JP2023536437A5 - - Google Patents
Info
- Publication number
- JP2023536437A5 JP2023536437A5 JP2023504833A JP2023504833A JP2023536437A5 JP 2023536437 A5 JP2023536437 A5 JP 2023536437A5 JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023536437 A5 JP2023536437 A5 JP 2023536437A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- erap2
- mhc
- hla
- inhibitor according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063056562P | 2020-07-25 | 2020-07-25 | |
| US63/056,562 | 2020-07-25 | ||
| US202163171672P | 2021-04-07 | 2021-04-07 | |
| US63/171,672 | 2021-04-07 | ||
| PCT/US2021/043062 WO2022026336A1 (en) | 2020-07-25 | 2021-07-23 | Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536437A JP2023536437A (ja) | 2023-08-25 |
| JP2023536437A5 true JP2023536437A5 (cg-RX-API-DMAC7.html) | 2024-07-30 |
Family
ID=77564145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504833A Pending JP2023536437A (ja) | 2020-07-25 | 2021-07-23 | 小胞体アミノペプチダーゼ2(erap2)媒介性免疫応答の調節 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12662539B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4188963A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023536437A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230043888A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116194484A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021316196B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3189755A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299986A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001059A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022026336A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3189755A1 (en) | 2020-07-25 | 2022-02-03 | Regeneron Pharmaceuticals, Inc. | Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response |
| WO2023064850A1 (en) * | 2021-10-14 | 2023-04-20 | Regeneron Pharmaceuticals, Inc. | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors |
| US12613286B2 (en) | 2024-01-22 | 2026-04-28 | Garrett Transportation I Inc. | System and method for battery parameter recharacterization |
| US12704384B2 (en) | 2024-05-28 | 2026-08-11 | Garrett Transportation 1 Inc. | Range estimation for battery electric vehicles |
| CN118593462B (zh) * | 2024-06-28 | 2026-01-27 | 沈阳药科大学 | 鼠尾草酸作为erap1的抑制剂在制备治疗强直性脊柱炎药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005269B2 (en) | 2002-06-06 | 2006-02-28 | The Regents Of The University Of California | ERAAP modulators regulate immune responses |
| WO2012009547A2 (en) | 2010-07-14 | 2012-01-19 | The Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| WO2012047294A2 (en) | 2010-10-06 | 2012-04-12 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy |
| US8969254B2 (en) | 2010-12-16 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Oligonucleotide array for tissue typing |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗-hla-b*27抗體及其用途 |
| ES2762403T3 (es) | 2012-04-26 | 2020-05-25 | Stichting Vumc | Biomarcadores |
| WO2014058976A2 (en) | 2012-10-10 | 2014-04-17 | Teva Pharmaceutical Industries Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| KR101748867B1 (ko) | 2013-04-19 | 2017-06-20 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 자동화 시스템 |
| EP3489369B1 (en) | 2013-06-25 | 2020-10-28 | Turun yliopisto | Method of predicting risk for type 1 diabetes |
| US9907833B2 (en) | 2013-07-25 | 2018-03-06 | University Of Florida Research Foundation, Incorporated | Use of relaxin to treat placental syndromes |
| US10927412B2 (en) | 2013-10-01 | 2021-02-23 | The Regents Of The University Of California | Endometriosis classifier |
| US10166210B2 (en) | 2014-06-12 | 2019-01-01 | Nsabp Foundation, Inc. | Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin |
| HK1257443A1 (zh) | 2015-08-21 | 2019-10-18 | The Children's Hospital Of Philadelphia | 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法 |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| GB201609712D0 (en) | 2016-06-03 | 2016-07-20 | Babraham Inst | Disease targets and biomarkers |
| US20190375842A1 (en) | 2018-01-04 | 2019-12-12 | Vanderbilt University | Check point inhibition in organ fibrosis |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11632728B2 (en) | 2019-07-18 | 2023-04-18 | Qualcomm Incorporated | Directional measurements for sidelink synchronization signal transmission |
| US12195723B2 (en) | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| WO2021113805A1 (en) | 2019-12-05 | 2021-06-10 | The General Hospital Corporation | Multi-biomarker prediction models for multiple infection episodes following blunt trauma |
| CA3189755A1 (en) | 2020-07-25 | 2022-02-03 | Regeneron Pharmaceuticals, Inc. | Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response |
-
2021
- 2021-07-23 CA CA3189755A patent/CA3189755A1/en active Pending
- 2021-07-23 JP JP2023504833A patent/JP2023536437A/ja active Pending
- 2021-07-23 MX MX2023001059A patent/MX2023001059A/es unknown
- 2021-07-23 US US17/384,601 patent/US12662539B2/en active Active
- 2021-07-23 WO PCT/US2021/043062 patent/WO2022026336A1/en not_active Ceased
- 2021-07-23 AU AU2021316196A patent/AU2021316196B2/en active Active
- 2021-07-23 CN CN202180052000.4A patent/CN116194484A/zh active Pending
- 2021-07-23 KR KR1020237005322A patent/KR20230043888A/ko active Pending
- 2021-07-23 EP EP21763171.2A patent/EP4188963A1/en active Pending
- 2021-07-23 IL IL299986A patent/IL299986A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102622309B1 (ko) | 염색체 상호작용의 검출 | |
| Merkel et al. | Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody–associated vasculitis | |
| Stone et al. | IgG4-related disease | |
| Puthia et al. | IRF7 inhibition prevents destructive innate immunity—A target for nonantibiotic therapy of bacterial infections | |
| CA2846307C (en) | Method for diagnosing a neurodegenerative disease | |
| US12188081B2 (en) | Bioinformatics methods of in silico validation and selection of circRNAs | |
| EP3538891A2 (en) | Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells | |
| Frade et al. | Polymorphism in the alpha cardiac muscle actin 1 gene is associated to susceptibility to chronic inflammatory cardiomyopathy | |
| Abe‐Hatano et al. | Whole genome sequencing of 45 Japanese patients with intellectual disability | |
| Lim et al. | Exome sequencing identifies KIAA1377 and C5orf42 as susceptibility genes for monomelic amyotrophy | |
| Maroilley et al. | Immunome differences between porcine ileal and jejunal Peyer’s patches revealed by global transcriptome sequencing of gut-associated lymphoid tissues | |
| Turkunova et al. | Molecular genetics and pathogenesis of the floating harbor syndrome: case report of long-term growth hormone treatment and a literature review | |
| CN116194484A (zh) | 内质网氨肽酶2(erap2)介导的免疫应答的调节 | |
| Hsu et al. | Effect of resistance training on satellite cells in old mice–a transcriptome study: Implications for sarcopenia | |
| Schramm et al. | Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates | |
| EP3013976B1 (en) | Method of predicting risk for type 1 diabetes before seroconversion | |
| Milazzo et al. | UBE3A reinstatement restores behaviorand proteome in an Angelman syndrome mouse model of imprinting defects | |
| JP2024515240A5 (cg-RX-API-DMAC7.html) | ||
| Gardet et al. | Pristane-accelerated autoimmune disease in (SWR X NZB) F1 mice leads to prominent tubulointerstitial inflammation and human lupus nephritis-like fibrosis | |
| JP2024521754A5 (cg-RX-API-DMAC7.html) | ||
| Ismail | Bioinformatics of Autoimmune Diseases | |
| ES2656587B1 (es) | Método para predecir la respuesta clínica a un tratamiento con agentes antiinflamatorios | |
| Zhang et al. | Associations of 2,922 genetically predicted plasma protein levels with mental illness and response to treatment | |
| Xiao et al. | HCV F protein amplifies the predictions of IL-28B and CTLA-4 polymorphisms about the susceptibility and outcomes of HCV infection in Southeast China | |
| Meijer et al. | A primed immune transcriptional program is activated in oligodendroglia in multiple sclerosis |